Gardner Lewis Asset Management L P Has $2.71 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Gardner Lewis Asset Management L P boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 35.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,995 shares of the company’s stock after purchasing an additional 4,955 shares during the period. Gardner Lewis Asset Management L P’s holdings in Novo Nordisk A/S were worth $2,711,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in NVO. Aveo Capital Partners LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $205,000. 9258 Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 4.0% during the 4th quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock valued at $260,000 after acquiring an additional 97 shares in the last quarter. Rollins Financial grew its holdings in shares of Novo Nordisk A/S by 10.4% during the 4th quarter. Rollins Financial now owns 3,894 shares of the company’s stock valued at $403,000 after acquiring an additional 368 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Novo Nordisk A/S by 38.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after acquiring an additional 26,067 shares during the last quarter. Finally, Gryphon Financial Partners LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter valued at $237,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 3.6 %

Shares of Novo Nordisk A/S stock opened at $132.00 on Wednesday. The company has a market cap of $592.35 billion, a price-to-earnings ratio of 45.52, a PEG ratio of 1.48 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $86.96 and a 1 year high of $148.15. The company’s fifty day simple moving average is $133.74 and its 200-day simple moving average is $133.20. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.11 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is presently 24.83%.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. Argus raised their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 19th. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.17.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.